ArticlePediatric nephrology (Berlin, Germany)2013
Serum microRNAs levels in primary focal segmental glomerulosclerosis.
Article in Pediatric nephrology (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Urinary Exosomal miRNAs as Non-Invasive Biomarkers Linked to Podocyte Morphometry in CKD.Cells · 2026Article
- miRNAs in Glomerular Diseases: From Pathogenic Insight to Therapeutic Potential: A Narrative Review.Cells · 2026Review
- Emerging roles of non-coding RNAs in idiopathic nephrotic syndrome: a narrative review.BMC nephrology · 2025Review
- Advances in focal segmental glomerulosclerosis research: genetic causes to non-coding RNAs.Molecular biology reports · 2025Review
- Pathogenic Role of MicroRNA Dysregulation in Podocytopathies.Frontiers in physiology · 2022Review
- Study on the Mechanism of circRNA Regulating the miRNA Level in Nephrotic Syndrome.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.Clinical kidney journal · 2021Review
- MicroRNAs as Biomarkers for Nephrotic Syndrome.International journal of molecular sciences · 2020Review
- Emerging role of miRNAs in renal fibrosis.RNA biology · 2020Review
- The Role of MicroRNAs in Selected Forms of Glomerulonephritis.International journal of molecular sciences · 2019Review
- Expression of miRNAs-122, -192 and -499 in end stage renal disease associated with acute myocardial infarction.Archives of medical science : AMS · 2019Article
- Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.Nature reviews. Nephrology · 2019Review
- Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.Kidney research and clinical practice · 2018Review
- Can microRNA profiles predict corticosteroid responsiveness in childhood nephrotic syndrome? A study protocol.BMJ paediatrics open · 2018Article
- MicroRNAs as Master Regulators of Glomerular Function in Health and Disease.Journal of the American Society of Nephrology : JASN · 2017Review
- Renal epithelial miR-205 expression correlates with disease severity in a mouse model of congenital obstructive nephropathy.Pediatric research · 2016Article
- High protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; association with diet/genetics-regulated micro-RNAs.Journal of diabetes & metabolism · 2016Article
- Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases.American journal of physiology. Renal physiology · 2016Review
- MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Annals of the New York Academy of Sciences · 2015Review
- Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.European journal of clinical investigation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs, miRs) are involved in most physiological, developmental, and pathological processes. miR-192 and miR-205 are expressed preferentially in the renal cortex and closely relevant to the renal cell biology. In the present study, we aim to measure the serum levels of miR-192 and miR-205 and their correlation with clinicopathological data in patients with primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
methodsFifty-six patients (35 male, 21 female) with idiopathic nephrotic syndrome (FSGS 30, MCD 26) and 20 healthy controls were enrolled in the study. We quantified the serum levels of miR-192 and miR-205 in patients with FSGS and MCD by RT-qPCR.
resultsPatients with FSGS had higher serum levels of miR-192 and miR-205 than those with MCD (324.49 ± 42.74 fmol/l versus 90.19 ± 27.14 fmol/l, p < 0.01, 2.25 ± 0.69 fmol/l versus 0.60 ± 0.51 fmol/l, p < 0.01, respectively). The level of miR-192 was positively correlated with the proteinuria in patients with FSGS and MCD (r = 0.62, p < 0.001, r = 0.84, p < 0.001, respectively). Similarly, the level of miR-205 was positively correlated with the proteinuria in patients with FSGS (r = 0.54, p = 0.002). In addition, the serum level of miR-192 was significantly correlated with the degree of interstitial fibrosis in patients with FSGS (r = 0.342, p < 0.05).
conclusionsmiR-192 and miR-205 have the potential as markers to differentiate FSGS from MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.